Prevention of infection in children with acute leukaemia. No major difference between total and selective bowel decontamination.
To evaluate the effect of total bowel decontamination (TD) and selective bowel decontamination (SD) in a non-protective environment clinical and laboratory data of children treated for acute leukaemia between 1983 and 1991 were analysed retrospectively. From 1983 until 1989 34 patients [18 acute non-lymphoblastic leukaemia (ANLL) patients, 16 acute lymphoblastic leukaemia (ALL) patients] received TD and 31 patients (8 ANLL patients, 23 ALL patients) received SD from 1987 until 1991. TD consisted of colistin sulphate, neomycin, cephaloridine and amphotericin B orally as well as Orabase and sterilized food, while the patients were nursed in a single room. SD consisted of oral colistin sulphate, neomycin and amphotericin B. Those patients with ANLL were nursed in a single room; patients with ALL were nursed in a single room during remission induction therapy only. All patients except those with ANLL receiving TD received Pneumocystis carinii pneumonia prophylaxis with cotrimoxazole. Because the two groups were heterogeneous for diagnosis and chemotherapy the occurrence of fever (central body temperature at least 38.5 degrees C) and major infections (septicaemia of infections of the deep tissues or organs) were registered during periods of neutropenia (neutrophilic granulocytes < or = 500/mm3 for at least 8 days). Patients on TD had 55 periods of neutropenia, patients on SD 80. Patients on TD had 89.1 periods of fever/100 periods of neutropenia whereas patients on SD had 56.3. Also patients on TD had 27.3 major infections/100 periods of neutropenia whereas patients on SD had 11.3. Major infections predominantly consisted of septicaemia caused by gram-positive bacteria. We conclude that, in this study, TD in a non-protective environment does not offer better protection against major infections that SD in patients with ALL or ANLL.
Muis
N
N
Paediatric Oncology Centre, University Hospital Groningen, The Netherlands.
Kamps
W A
WA
Dankert
J
J
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000382:microbiology; D001424:Bacterial Infections / Q000517:prevention & control*; D002266:Carboxymethylcellulose Sodium / Q000031:analogs & derivatives / Q000627:therapeutic use; D002509:Cephaloridine / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003091:Colistin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D005511:Food Handling; D016905:Gram-Negative Bacterial Infections; D006801:Humans; D007223:Infant; D007422:Intestines / Q000382:microbiology*; D015470:Leukemia, Myeloid, Acute / Q000451:nursing / Q000628:therapy*; D009355:Neomycin / Q000627:therapeutic use; D009503:Neutropenia / Q000150:complications; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000451:nursing / Q000628:therapy*; D012189:Retrospective Studies; D013242:Sterilization; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000666:Amphotericin B; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C056627:Orabase; D009355:Neomycin; D002266:Carboxymethylcellulose Sodium; D002509:Cephaloridine; D003091:Colistin